424B4PROSPECTUS
May 19, 2026Final prospectus0001683168-26-004098
All companies
Trade Sunshine Biopharma Inc424B4May 19, 2026
Sunshine Biopharma plans $6M unit offering | SBFM IPO Registration (S-1) SUNSHINE BIOPHARMA INC. S-1 Sunshine Biopharma offers $6.0M via 11.16M units | SBFM Prospectus Summary Sunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
SU
Sunshine Biopharma Inc
SBFMPublicArchived
Public / ArchivedUnited States(Nasdaq)Best valuation $4.35M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
SBFMPrice
$2.05
24h
-3.76%
Valuation
$4.35M
24h volume
$168.99K
Type
IPO
Trade Sunshine Biopharma IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Sunshine Biopharma Inc IPO public float & lock-up
Public float and locked shares extracted from Sunshine Biopharma Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
17.01M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001402328.
Revenue · +4.11% YoY
$36.31M
Net income
-$5.98M
Gross margin
33.76%
Cash
$21.83M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $36.31M | $34.87M | $24.09M | $4.35M | $228.43K |
| Gross profit | $12.26M | $10.67M | $8.34M | $1.7M | $110.6K |
| Operating income | -$6.23M | -$5.81M | -$4.79M | -$27M | -$2.44M |
| Net income | -$5.98M | -$5.13M | -$4.51M | -$26.74M | -$12.44M |
| R&D expense | $604.31K | $933.9K | $1.86M | $811.86K | $672.21K |
| Cash & equivalents | — | — | — | $21.83M | $2.05M |
| Total assets | $30.08M | $30.56M | $27.35M | $29.24M | $2.2M |
| Total liabilities | $7.04M | $7.06M | $6.14M | $7.62M | $1.99M |
| Shareholders' equity | $23.04M | $23.5M | $21.21M | $21.63M | $211.66K |
About Sunshine Biopharma Inc
Sunshine Biopharma is a pharmaceutical company with generic prescription drugs, over-the-counter products, and proprietary drug-development programs.
What the company does
- Operates through subsidiaries including Nora Pharma, which markets generic prescription drugs in Canada.
- Develops or researches proprietary programs in therapeutic areas such as oncology and antivirals.
- Combines commercial pharmaceutical distribution with earlier-stage research and product-development activities.
Business profile
Sunshine Biopharma operates in pharmaceuticals, where regulatory approvals, product portfolio breadth, manufacturing and distribution quality, and clinical execution are central.
SEC IPO filings
Final prospectusEDGAR filings resolved from SBFM / CIK 0001402328.
May 18, 2026Effective9999999995-26-001691
CORRESPfilename1.htm
May 18, 2026SEC correspondence0001683168-26-004050
CORRESPfilename1.htm
May 18, 2026SEC correspondence0001683168-26-004049
CORRESPfilename1.htm
May 14, 2026SEC correspondence0001683168-26-003939
CORRESPfilename1.htm
May 14, 2026SEC correspondence0001683168-26-003938
S-1FORM S-1
May 12, 2026Filed0001683168-26-003726
UPLOADfilename1.pdf
May 4, 2026SEC correspondence0000000000-26-004519
DRSLTRfilename1.htm
Apr 28, 2026Confidential draft0001683168-26-003260
Apr 28, 2026Confidential draft0001683168-26-003259
Aug 12, 2025Effective9999999995-25-002587
424B3PROSPECTUS
Aug 12, 2025Final prospectus0001683168-25-005978
Latest Sunshine Biopharma Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
StockTitanIPO filing
Reports the company’s S-1 registration filing for its own public offering.
U.S. SEC (EDGAR)IPO filing
Primary source for the company’s S-1 filing (IPO/public offering-related).
StockTitanIPO context
Prospectus update describing the company’s $6.0M public offering terms (offering context).
NasdaqIPO context
Company-specific offering pricing and exchange uplisting context.
Sunshine Biopharma Inc IPO — frequently asked questions
- When did Sunshine Biopharma Inc go public?
- Sunshine Biopharma Inc has already gone public and now trades publicly on Nasdaq under the ticker SBFM.
- Can I buy Sunshine Biopharma Inc stock?
- Yes — Sunshine Biopharma Inc is publicly traded on Nasdaq as SBFM. You can follow its live price, valuation and post-IPO performance above.
- What is Sunshine Biopharma Inc's valuation?
- Sunshine Biopharma Inc's most recent valuation tracked here is $4.35M, derived from live market prices.